

Title	A national case fatality study of drugs taken in intentional overdose
Authors	Daly, Caroline;Griffin, Eve;Corcoran, Paul;Webb, Roger T.;Ashcroft, Darren M.;Perry, Ivan J.;Arensman, Ella
Publication date	2019-12-26
Original Citation	Daly, C., Griffin, E., Corcoran, P., Webb, R. T., Ashcroft, D. M., Perry, I. J. and Arensman, E. (2020) 'A national case fatality study of drugs taken in intentional overdose', International Journal of Drug Policy, 76, 102609 (9 pp). doi: 10.1016/j.drugpo.2019.102609
Type of publication	Article (peer-reviewed)
Link to publisher's version	<a href="http://www.sciencedirect.com/science/article/pii/S0955395919303160">http://www.sciencedirect.com/science/article/pii/S0955395919303160</a> - 10.1016/j.drugpo.2019.102609
Rights	© 2019 Elsevier B.V. All rights reserved. This manuscript version is made available under the CC BY-NC-ND 4.0 licence. - <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</a>
Download date	2024-04-27 03:18:51
Item downloaded from	<a href="https://hdl.handle.net/10468/9457">https://hdl.handle.net/10468/9457</a>

**Title: A national case fatality study of drugs taken in intentional overdose**

Caroline Daly<sup>a</sup>, Eve Griffin<sup>a</sup>, Paul Corcoran<sup>a,b</sup>, Roger T. Webb<sup>cd</sup>, Darren M. Ashcroft<sup>c,e</sup>, Ivan J. Perry<sup>b</sup>,  
Ella Arensman<sup>a,b,f</sup>

<sup>a</sup> National Suicide Research Foundation, Room 4.28, Western Gateway Building, Western Road, Cork, Ireland

<sup>b</sup> School of Public Health, University College Cork, Western Gateway Building, Western Road, Cork, Ireland

<sup>c</sup>NIHR Greater Manchester Patient Safety Translational Research Centre, Suite 11, Floor 7, Williamson Building Faculty of Biology, Medicine and Health Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, The University of Manchester, Oxford Road, Manchester, M13 9PL, England

<sup>d</sup> Manchester Academic Health Sciences Centre (MAHSC), The University of Manchester, Oxford Road, Manchester, M13 9PL, England

<sup>e</sup> Manchester Pharmacy School, The University of Manchester, 1st Floor Stopford Building, Oxford Road, Manchester, M13 9PT, England

<sup>f</sup> Australian Institute for Suicide Research and Prevention, Room 1.48 Psychology Building (M24), Griffith University Messines Ridge Road, Mount Gravatt, Queensland, 4122, Australia

**Corresponding author**

*Ms Caroline Daly,*

National Suicide Research Foundation, Ireland

Postal address: Room 4.28, Fourth Floor, National Suicide Research Foundation, Western Gateway Building, Western Road, Cork, Ireland.

Email: carolinedaly@ucc.ie

**Funding source**

Co-funded by the National Suicide Research Foundation, the National Office for Suicide Prevention and the University of Manchester.

## **Title: A national case fatality study of drugs taken in intentional overdose**

### **Abstract**

#### **Background**

Intentional drug overdose (IDO) has been linked with marked increases in mortality due to suicide, accidents and other causes, yet little is known about how case fatality risk varies according to the type of drug/s taken. This study aimed to examine the incidence fatal and non-fatal IDO, to identify the predictors of fatal IDO and to establish which drug types are linked with greater risk of a fatal outcome.

#### **Methods**

Data from the National Self-Harm Registry, Ireland and the National Drug-Related Deaths Index, 2007-2014, were used to calculate incidence, examine overdose characteristics and estimate case fatality risk ratios.

#### **Results**

We examined 63,831 non-fatal and 364 fatal IDOs (148.8 and 1.01 per 100,000 respectively). Compared to non-fatal IDOs, fatal cases were often male (55.2% vs. 42.0%), older in age (median 44 vs. 35 years), and more frequently involved multiple drugs (78.3% vs. 48.5%). Tricyclic antidepressants were associated with a 15-fold increased risk of death and opioids a 12-fold increased risk, relative to the reference category (non-opioid analgesics). While the risk of fatal outcome was higher for males than females, the elevation in risk was greater in females when tricyclic antidepressants or opioids were taken in IDO.

#### **Conclusion**

Male gender, increasing age and multiple drug use were associated with fatal IDO outcome. Tricyclic antidepressants and opioids were associated with a significantly increased risk of death following overdose. Clinicians need to consider the case fatality risk of drugs when determining treatment for patients at risk of or those who have previously harmed themselves.

**Keywords:** self-harm; suicide; overdose; drugs; antidepressants

**Introduction:** Intentional drug overdose (IDO) is the most common method of hospital-presenting non-fatal self-harm (Perry, et al., 2012; Vancayseele, Portzky, & van Heeringen, 2016), and is associated with an increased risk of repeat self-harm (Finkelstein, et al., 2016), which when combined with another method, such as self-cutting, can increase by 50% (Kwok, Yip, Gunnell, Kuo, & Chen, 2014). The risk of mortality due to suicide is also increased among persons who have engaged in IDO, as are deaths due to other causes, including accidental deaths, those of undetermined intent and those caused by underlying disease (Finkelstein, Macdonald, Hollands, Hutson, et al., 2015a; Finkelstein, Macdonald, Hollands, Sivilotti, et al., 2015b).

Intentional drug overdose resulted in 7,792 presentations to Irish hospitals in 2018 (Griffin, et al., 2019), and accounts for approximately 68-84% of all hospital treated self-harm presentations, most of which involve females and persons under 40 years of age (Daly, et al., 2018; Vancayseele, Rotsaert, Portzky, & van Heeringen, 2019). Fatal IDO results in approximately 40 deaths in Ireland annually (CSO, 2014), and accounted for approximately 889 deaths in England and Wales in 2018 (ONS, 2019), of which the majority were male. Considering drugs taken, non-fatal IDOs most frequently involve non-opioid analgesics, antidepressants and hypnotics and sedative (including benzodiazepines) drugs (Daly, et al., 2018; Vancayseele, et al., 2019), and fatal IDOs most commonly involve opioid and benzodiazepine drugs (HRB, 2015; Pringle, et al., 2017).

The type of drug taken in IDO varies according to individual characteristics, geography and across time periods, and is one of several key factors that influence the likelihood of repeat IDO and subsequent fatality following overdose (Finkelstein, et al., 2016; Geulayov, et al., 2018). Research in the UK which measured case fatality of single-drug overdoses with antidepressants and benzodiazepines attributed high fatality to the antidepressants dosulepin doxepin, citalopram (Hawton, et al., 2010), and to the benzodiazepine and hypnotic drugs temazepam and zopiclone/zolpidem (Geulayov, et al., 2018). A subsequent study in the USA examined the fatality of drugs used in all poisoning deaths (intentional and accidental) over a 16-year period, and identified opioids as the most toxic drug examined, followed by tricyclic antidepressants (Brett, Wylie, Raubenheimer, Isbister, & Buckley, 2019).

Establishing the potential fatality of and IDO is undermined by the frequent involvement of a combination multiple drugs in overdose. Multiple drugs are present in between 26 and 41% of non-fatal IDOs (Daly, et al., 2018; Finkelstein, et al., 2016), increasing to 64% in fatal overdoses (HRB, 2015). Despite the

involvement of multiple drugs in non-fatal and particularly fatal IDO, the case fatality of drugs taken in multiple drug overdoses remains under examined and has not yet been established in relation to suicide deaths. Insights into the case fatality of drugs used in both single and multiple drug IDOs which would aid clinicians in determining assessment and treatment pathways for patients who are at risk of or have previously engaged in IDO.

This study aimed to identify the incidence and characteristics of fatal and non-fatal IDO, including single and multiple drug IDOs, and, to establish which drug types are most strongly linked with a fatal outcome, according to case fatality risk estimates.

**Method:** This was an observational study using data pertaining to the period 1<sup>st</sup> Jan 2007 to 31<sup>st</sup> Dec 2014, which examined two unlinked datasets that captured fatal IDO cases in the National Drug-Related Deaths Index, Ireland (NDRDI) and non-fatal IDO presentations in the National Self-Harm Registry, Ireland (NSHRI).

#### *Non-fatal hospital-treated IDO presentations*

The NSHRI, which is administered by the National Suicide Research Foundation (NSRF), monitors hospital-treated self-harm across all 36 acute hospitals in the Republic of Ireland, using the following definition of self-harm: 'an act with non-fatal outcome in which an individual deliberately initiates a non-habitual behaviour, that without intervention from others will cause self-harm, or deliberately ingests a substance in excess of the prescribed or generally recognised therapeutic dosage, and which is aimed at realising changes that the person desires via the actual or expected physical consequences' (Platt, et al., 1992). Data on self-harm presentations are collected by Data Registration Officers (DROs), including items detailing: sex, age, area of residence, date and hour of hospital attendance, whether the individual arrived by ambulance, method(s) of self-harm, drugs taken, medical card status, mental health assessment and recommended next care received. A maximum of 5 methods are recorded for presentations involving multiple methods. We examined non-fatal IDO presentation-based data, identified as having ICD-10 codes X60-X64. Presentations of IDO involving other agents, such as chemicals (ICD-10 X66-X69), and alcohol-only self-poisoning cases (ICD-10 X65) were excluded. Drugs taken in IDO are captured in the NSHRI via self-reported information from the patient, ambulance service records, hospital medical records, and toxicology reports if available. Information pertaining to a maximum of 10 drugs taken in IDO were examined.

### *Fatal IDO cases*

Deaths by IDO were identified via the NDRDI, which records all deaths by drug and/or alcohol poisoning, and deaths among drug users and those who are alcohol dependent, in persons aged over 15 years in the Republic of Ireland. Fatal cases where the coroner returned a suicide or 'open' verdict (i.e. unnatural death of undetermined cause), following a completed inquest procedure, were included in this study. Open verdicts are customarily included in suicide statistics as these cases have been shown to have similar characteristics to suicides, often representing probable suicides where the evidence was insufficient to prove that the individual intended to take their own life (Linsley, Schapira, & Kelly, 2001). Fatal IDO cases are those that occurred directly due to the toxic effects of the drug(s) taken. Non-poisoning deaths, deaths by alcohol only (ICD-10 X65), chemical poisonings (ICD-10 X66-X69), and deaths with no coronial verdict, or with a verdict of misadventure, were excluded. Relevant information collected on each fatal IDO case included: sex, age date of death and post-mortem toxicology results - including whether a drug was involved in death or caused the death, as reported on the individual's death certificate.

### *Drugs certified as a cause of death or involved in death*

Post-mortem blood and urine samples are screened in local hospital laboratories using immunoassay analysis to identify the involvement of particular drugs in death. Further identification and quantification, is provided by the State Laboratory for Human Toxicology which, together with information from the State Pathologist, assists the responsible Coroner in interoperating whether or not to certify a drug as involved in death or as causing the death. One or more drugs can be registered in the individuals' certificate as being involved in death or as having caused death.

### *Classification of drugs*

We reported on the drug types frequently used in IDO, as determined by Daly et al., 2018 (Daly, et al., 2018). The Anatomical Therapeutic Chemical (ATC) classification system was applied to the drugs examined in this study, the detail of which can be found in the Guidelines for ATC Classification and DDD Assignment (WHO, 2019). The ATC codes for the drug types reported are: psycholeptics 'N05'; analgesics 'N02'; opioids 'N02A'; morphine containing drugs 'N02AA01', 'N02AG01', 'N02AA51'; oxycodone containing drugs 'N02AA05', 'N02AJ17', 'N02AJ18', 'N02AJ19'; tramadol containing drugs 'N02AX02', 'N02AJ13', 'N02AJ14', 'N02AJ15'; non-opioid analgesics 'N02B' and 'N02C'; hypnotics and

sedatives 'N05C'; antipsychotics; 'N05A'; psychoanaleptics 'N06'; selective serotonin reuptake inhibitors (SSRIs) 'N06AB'; fluoxetine 'N06AB03'; citalopram 'N06AB04'; sertraline 'N06AB06'; tricyclic antidepressants 'N06AA'; amitriptyline 'N06AA09'; dosulepin 'N06AA16'; trimipramine 'N06AA06'; antiepileptics 'N03'; benzodiazepines 'N03AE', 'N05BA', 'N05CD' and 'N05CF'. Illicit drugs were identified using the Irish Misuse of Drugs Acts of 1977 and 1984 (Misuse of Drugs Act 1977, Misuse of Drugs Act 1984); and are listed in the Supplementary Material, item 'Illicit Drugs List'. Multiple drug use refers to the involvement of two or more distinct drug types per IDO presentation, whereas single drug use refers to the taking of just one drug type, both of which excluded alcohol misuse.

### *Statistical analyses and reporting*

Annual gender- and age-specific incidence rates per 100,000 persons were calculated using the numbers of non-fatal and fatal IDO cases recorded and the national Census population data for 2011 and the Central Statistics Office annual population estimates for other years. We calculated 95% confidence intervals using the Poisson distribution. Case fatality risk represent the proportion of IDOs which are fatal according to the demographic or drug group under examination. Case fatality risk ratios represent the ratio of the case fatality risk of the particular demographic or drug group being examined relative to the reference category. Non-opioid analgesics were chosen as the reference category for drugs examined in Table 2 as they are among the most frequently used drugs taken in IDO (Daly, et al., 2018). The reference categories for Table 3 are amitriptyline, and tramadol and fluoxetine, which represent the most common tricyclic antidepressants, SSRIs and opioids used in IDO, respectively. Case fatality risk ratios presented within the main text of the paper refer to drugs that were certified by Coroners' certificates as being the cause of death, and were calculated from an age- and gender-adjusted Poisson regression model. An additional sensitivity analysis was conducted to estimate the case fatality risk ratios of drugs involved in death, and are provided in the Supplementary Material (Table 2, 5 and 6).

A process of weighting was performed to address the challenge of calculating case fatality risk and case fatality risk ratios when multiple drugs had been certified as causing death. Case fatality risk ratios presented within this paper are weighted, whereby the drug of interest is counted as half within the reference drug group and half within the drug group of interest, in which the two aforementioned drug groups were attributed 50% of the fatality risk. A series of sensitivity analysis were conducted to

calculate alternative case fatality risk ratio estimates whereby the drug of interest was either counted in both its drug group or that of the reference group ('Double count') or in neither ('Excluded in count'). These additional sensitivity analyses, which are provided in the Supplementary Material (Tables 2, 4 and 5), offer alternative analytical approaches for estimating the relative fatality of IDOs according to the type of drug (or drugs) taken.

Cell counts of less than five for fatal cases were masked in all tabulations. Analyses were conducted using SPSS v.22. Statistical significance was reported at three thresholds:  $p \leq 0.05$ ,  $p \leq 0.01$  and  $p \leq 0.001$ . The conventional levels of  $p \leq 0.05$ ,  $p \leq 0.01$  are reported to allow for comparability with other research. The stringent threshold of  $p \leq 0.001$  was used to highlight the most significant associations, which is important when examining a dataset of this size. Case fatality risk ratio weighting was performed using Excel formulae, and StataIC 12 was subsequently employed to calculate the case fatality risk ratios and accompanying confidence intervals and significance values.

The reporting of this study conforms to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

#### Ethical approval

The NSHRI has ethical approval from the National Research Ethics Committee of the Faculty of Public Health Medicine, Ireland. The NSHRI operates under a policy approving a waiver of consent. These patients have the right to opt out of having their data collected and used for research via a system that is described in patient leaflets placed in the emergency department, and reserve all the rights of data subjects as outlined in the current General Data Protection Regulation (GDPR) 2018 regulations. The NDRDI has ethical approval from the Health Research Board (HRB) ethics committee.

#### Data access

The NSRF is registered with the Data Protection Agency and complies with the Irish Data Protection Act of 1988 and the Irish Data Protection (Amendment) Act of 2003. All data were anonymised and stored on a secure server in a restricted access location and accessed only on a Symantec encrypted computer.

#### Financial support

This study was co-funded by the NSRF and by the University of Manchester, under no specific grant funding. The NSHRI is funded by the Health Service Executive's National Office for Suicide Prevention.

## Results

### *Characteristics of non-fatal and fatal IDOs*

Between 1<sup>st</sup> January 2007 and 31<sup>st</sup> December 2014 there were 64,195 IDOs, 63,831 of which were non-fatal, and 364 of which were fatal. Of the fatal IDO cases, 46.2% (168) had received a verdict of suicide and 196 an open verdict. The majority of fatal cases were male (55.2%) and the median age of these persons was 44 years (IQR: 33-53). Non-fatal IDO presentations were most often made by females (58.0%) and the median age reported was 35 years (IQR: 23-44). Multiple drug use was a factor in 78.3% of fatal IDOs and 48.5% of non-fatal episodes.

[Figures 1a and 1b here]

### *Incidence of non-fatal and fatal IDOs*

Figures 1a and 1b illustrate the non-fatal and fatal IDO incidence rates stratified by age and gender. Overall, the rate of non-fatal IDO was 148.8 per 100,000 (95% CI 147.5-150.1) and the rate of fatal IDO was 1.01 (0.90-1.11). The incidence of non-fatal IDO was higher for females and peaked for persons aged 15-24 years whereas the rate of fatal IDO was higher for males and highest among persons aged 45-54 years, as illustrated in Table 1 and reported in Supplementary Table 1.

[Table 1 here]

### *Case fatality by gender, age and number of drugs*

Examining case fatality, the risk of death following an IDO was 1.7 times greater for males, compared to females (CFRR=1.70; 1.38-2.09,  $p \leq 0.001$ ), as reported in Table 1. The risk of death increased with age and was over five times greater for those aged 45 years or older (CFRR=5.63; 3.91-8.11,  $p \leq 0.001$ ), compared to those aged 15-24 years. Multiple drug IDOs were over three times more likely to be fatal compared to single drug IDOs (CFRR=3.80; 2.96-4.88,  $p \leq 0.001$ ). Intentional drug overdoses involving between two and five different drugs were three times more likely to be fatal (CFRR=3.13; 2.43-4.04,  $p \leq 0.001$ ) and those that involved six or more distinct drugs ( $n=365$ ) were also significantly

more likely to result in death (CFRR=60.5; 42.7-85.7,  $p \leq 0.001$ ), compared to IDOs involving one drug. The involvement of alcohol did not increase risk of death in this study (CFRR=1.07; 0.87-1.32,  $p=0.538$ ).

[Table 2 here]

#### *Drugs frequently taken in IDO*

Psycholeptic drugs, the majority of which were benzodiazepines, were the drug type that most frequently caused death or were involved in non-fatal IDO, as reported in Table 2. Considering non-fatal IDOs, non-opioid analgesics were also frequently taken, with an incidence rate of 50.0 per 100,000 (49.3-50.8). Opioid and tricyclic antidepressant drugs had the lowest rates of involvement in non-fatal IDO at 7.85 (7.56-8.15) and 3.63 per 100,000 (3.43-3.83), respectively. Examining fatal IDOs, the frequent use of psycholeptic drugs was followed by antidepressant drugs at 0.39 (0.33-0.46). Owing to the larger number of female non-fatal IDO presentations, compared to males, the rates for all drugs used in non-fatal acts, excluding illicit drugs are higher for females. Greater gender disparities are reported for fatal IDOs, where females have higher rates of IDOs involving antipsychotic and antidepressant drugs, as illustrated in Table 2. The incidence patterns were similar for drugs that were involved in death and for drugs involved in single drug IDOs, as reported in Supplementary Tables 2 and 3.

#### *Case fatality of drugs which caused death*

Table 2 reports on the case fatality of drugs that were deemed ultimately by the Coroners to have caused death. The risk of death following IDO was 15 times greater when a tricyclic antidepressant was taken (CFRR=15.1; 9.90-23.12,  $p \leq 0.001$ ), compared to the reference drug category (non-opioid analgesics). Opioid drugs were associated with over a 12-fold increased risk of death (CFRR=12.9; 8.60-19.3,  $p \leq 0.001$ ). Both antidepressant and illicit drug IDOs were over four times more likely to result in death (CFRR=4.46; 3.06-6.49,  $p \leq 0.001$  and CFRR=4.02; 2.36-6.86,  $p \leq 0.001$ ). Antiepileptic and anxiolytic drugs were associated with the lowest fatality risk ratios among the drug types examined (CFRR=1.96; 1.17-3.29,  $p=0.010$  and CFRR=2.08; 1.39-3.10,  $p \leq 0.001$ ).

Examining fatality risk by gender, as shown in Table 3, the elevation in risk compared to the reference drug for females, was approximately three times the risk elevation of males when tricyclic antidepressants were taken (CFRR=23.6; 13.0-43.0,  $p \leq 0.001$  vs. 9.02; 4.74-17.2,  $p \leq 0.001$ ), a disparity

which was not apparent for female vs. male SSRI overdose IDO (CFRR=3.01; 1.73-5.24,  $p \leq 0.001$  vs. 3.32; 1.80-6.13,  $p \leq 0.001$ ). When illicit drugs were taken in IDO the risk of a fatal outcome is slightly elevated for males, compared to females (CFRR=4.20; 2.27-7.76,  $p \leq 0.001$  vs. 3.29; 1.00-10.8,  $p \leq 0.001$ ). These patterns were essentially replicated when drugs involved in death were examined, although the magnitude of the difference was smaller; and also when we implemented alternative approaches for estimating the case fatality risk ratio, as reported in Supplementary Tables 5 and 6. Considering single drug IDOs, opioids were the drug type identified as most fatal in IDO (CFRR=11.69; 3.73-36.7,  $p \leq 0.001$ ), as highlighted in the Supplementary Table 3. The alternative means by which CFRR were calculated (double count and excluded in count) are presented, with very minor variations in estimates found, as reported in Supplementary Table 4).

#### *Case fatality of individual drugs which caused death*

Considering individual tricyclic drugs, trimipramine or dosulepin were not found to confer any additional risk of death, compared to amitriptyline (CFRR=0.73; 0.18-3.02,  $p=0.662$  and CFRR=0.93; 0.49-1.76,  $p=0.827$  respectively), as reported in Table 3. Consuming the SSRI citalopram in IDO was associated with a 5-fold increased risk of death, compared to fluoxetine (CFRR=5.26; 2.55-10.85,  $p \leq 0.001$ ). Both morphine and oxycodone, which are opioid drugs, were associated with significant increased risk of fatality following IDO, compared to the reference drug tramadol (CFRR=4.16; 2.11-8.19,  $p \leq 0.001$  and CFRR=3.94; 2.30-6.77,  $p \leq 0.001$ ). This elevation in risk was higher for females than males, particularly so when morphine was consumed in IDO (CFRR=6.67; 2.54-17.5,  $p \leq 0.001$  vs. CFRR=2.85; 1.12-7.28,  $p=0.028$ ), as illustrated in Table 3.

## **Discussion**

#### *Main findings and interpretation*

To our knowledge this is the first study which estimated case fatality risk associated with IDOs involving multiple drug types, which we examined using robust data from two national routinely collected datasets. We found that tricyclic antidepressants and opioid drugs are associated with a significantly increased risk of death following IDO, and this relative risk was greater in females than males when these drugs were taken. Male gender, increasing age and multiple drug use were found to be strong predictors of fatality in IDO.

The consumption of tricyclic antidepressants in IDO was linked with an approximate 15-fold increased risk of subsequent death versus non-opioid analgesics. The findings of this study builds upon other research that has attributed a high level of toxicity to tricyclic antidepressants (Hawton, et al., 2010). The UK National Institute for Health and Care Excellence (NICE) clinical guideline (CG133) 2011, recommends “When prescribing drugs for associated mental health conditions to people who self-harm, take into account the toxicity of the prescribed drugs in overdose...In particular, do not use tricyclic antidepressants, such as dosulepin, because they are more toxic” (NHS, 2011). However, Carr *et al.*, 2016 identified that approximately one in ten patients who have recently harmed themselves continue to be prescribed these drugs (Carr, et al., 2016). Subsequent NICE pathway guidelines continue to emphasise the risk of IDO with tricyclic antidepressants in persons with identified suicide risk (NICE, 2018). Considering the risks of fatal overdose which are associated with tricyclic antidepressants, action beyond recommendations is perhaps needed in order to protect patients at risk of overdosing with these drugs. Within this study no individual tricyclic antidepressant stood out as attributing excessive case fatality which is dissimilar to previous research which identified dosulepin and doxepin as more toxic than other tricyclic drugs (Hawton, et al., 2010), which could be due to the involvement of small numbers of individual tricyclics in fatal IDOs. However, the identification of the SSRI citalopram as five times more toxic than the reference SSRI drug (fluoxetine) builds upon the finding of excessive risk associated with this particular drug by Hawton et al., 2010. Therefore, notwithstanding the current evidence which recommends SSRI prescribing in the place of tricyclics, where appropriate and indicated, the risk associated with SSRIs, particularly citalopram cannot be undermined.

Despite having a relatively low rate of involvement in IDO among the drug types examined, opioids were associated with a 12-fold increased risk of death following IDO, versus non-opioid analgesics. The rate of non-fatal opioid IDO identified in this study (7.70 per 100,000; 95% CI: 7.41-8.00) is similar to the most recent national prevalence estimates of opioid users in Ireland, as of 2014, (6.18 per 100,000; 95% CI: 6.09-6.98). The OECD recently reported that the recent increases in opioid deaths in Ireland was among the most pronounced of the 25 countries examined, whereby the rate per million inhabitants stands at one third that of the USA (43.5 versus 131.0 per million) (OECD, 2019), highlighting a significant threat to public health. The fatality of an opioid overdose has been found to increase if: the overdose involves the co-ingestion of other drugs (predominantly benzodiazepines) (Sgarlato & deRoux, 2015), the individual had a prescription for opioids within 30 days of death (Austin,

Proescholdbell, Creppage, & Asbun, 2017), the patient was on a high dose of opioid prescription (Bohnert, et al., 2011; Ilgen, et al., 2016), and if the individual had previous opioid overdose hospitalisation (Kelty & Hulse, 2017). One commonality between these precipitating factors is the involvement of a healthcare professional, signalling an opportunity for intervention, however the evidence base for measures to reduce opioid overdose deaths is not yet comprehensive. Some emerging evidence illustrate effectiveness for naloxone distribution interventions (McDonald & Strang, 2016) and treatments involving medications for opioid use disorder (Sordo, et al., 2017). A systematic review by Frank et al., 2017 also found some evidence, albeit of low quality, supporting opioid tapering in an environment whereby the patient is monitored for any adverse effects of dose-tapering (Frank, et al., 2017). Considering the high potential for fatality following opioid IDO and the established increase in opioid deaths, additional research, of greater quality, is needed to examine the potential impact, including dangers, associated with risk reduction measures.

Benzodiazepines are among the most frequently used drugs taken in IDO, yet the risk of death following IDO involving these drugs was among the lowest of the drug groups examined. This finding, albeit with a weaker observed association, concurs with findings reported from other research (Geulayov, et al., 2018). Measures identified to reduce repeat or fatal IDO with benzodiazepines include: conducting an assessment of suicide risk with patients prior to prescribing a benzodiazepine (Dodds, 2017), and lowering benzodiazepine dosage (Okumura & Nishi, 2017), however whilst dose-tapering, in conjunction with non-pharmacological interventions are effective benzodiazepine discontinuation measures, similar to the use of does-tapering intervention for opioid overdose, it is unknown whether reduction strategies could result in potential adverse effects for patients ( Canadian Agency for Drugs and Technologies in Health, 2015). Another outstanding key factor warranting further research is the frequency with which benzodiazepines are being prescribed with other potentially toxic medications, including opioids, as this can increase the risk of a fatal outcome.

In line with the wider literature on self-harm and suicide, the incidence of non-fatal IDO reported in this study were higher for females (Finkelstein, et al., 2016) although risk of dying by IDO was higher for males (Jansen, Buster, Zuur, & Das, 2009). This paradox is often attributed to gender-related differences in method choice (Cibis, et al., 2012), intent (Freeman, et al., 2017) or the disproportionate gender distribution of depressive disorders (Alonso, et al., 2004). The increased fatality for males identified in this study, which examines IDO only, suggests that factors excluding method choice are

accountable for differences in case fatality between genders. This study identifies variability in drug types taken by males and females as impacting upon risk of death following IDO. However, as female fatality risk was elevated for all drug groups examined except illicit drugs, drug type is unlikely to account for the greater risk of a fatal outcome following overdose among males. To this end, more research is needed to elucidate the mechanisms that explain gender differences in fatality risk following IDO.

Fatal IDO cases in this study were older than non-fatal cases. Lower case fatality in younger age has been attributed to better overall health status, lesser suicidal intent and increased chance of survival, compared to older persons (Jansen, et al., 2009). Conversely, accessibility to prescribed medications and better knowledge of the lethality of medications among older people has been used to explain their increased risk of fatality following IDO (Schmidtke, 2004). Considering the finding by Chen et al., 2009 that the effect of age on fatality is stronger for poisoning compared to other methods of self-harm (Chen, et al., 2009), the link between growing age and increasing fatality, identified by this study, is an important consideration for the prevention of suicide by IDO in older persons. Prescribers should remain cognisant of the medication load of older patients and monitor for and respond to indicators of drug misuse within this subgroup. In particular, prescribing of drugs including those with established toxicity, should be reviewed before long term-use is established to ensure patient safety which in which the therapeutic effects are balanced against the risk of potential harm from such drugs (Bedson, et al., 2019).

The involvement of multiple drugs in almost half of all non-fatal IDOs and approximately 80% of fatal IDOs identified in this study is significantly greater than found in previous comparative studies (Finkelstein, et al., 2016; HRB, 2015; Vancayseele, et al., 2016). Considering that the fatality of an IDO increases significantly as the number of drugs used in combination increases, the importance of restricting or avoiding multiple drug prescribing, when possible, is indicated by our findings. As successful suicide prevention required multiple level interventions, such means restriction measures should also be accompanied by treatments at individual level, to be provided by the mental health and allied services, including patient education, effective pharmacological and psychological treatments (Zalsman, et al., 2016).

#### *Strengths and limitations*

Our study has important strengths, including the use of robust national data covering an eight-year period. The utilisation of two datasets with full national coverage, capturing all non-fatal hospital-based

IDO presentations and all deaths due to IDO, respectively, is a unique strength of this study. The examination of case fatality of both single and multiple drug IDOs, and the novel analytical approach used to test case fatality estimates paves the way for future researchers to expand beyond examinations of fatality following single drug overdose. Furthermore, the examination of drugs identified as being a cause of death (as determined by the Coroner) and those involved in death (as indicated in toxicology) adds to the robustness of our findings and strengthens the conclusions drawn.

The results of this study should be interpreted in the context of its limitations. Owing to the absence of a common unique patient identifier in both datasets examined it was not possible to perform data linkage. Thus, the case fatality risks reported represent an approximation of fatality risk between unlinked non-fatal and fatal IDO cases. Confounding by indication an important consideration when interpreting the study findings, as persons taking drugs with high case fatality estimates may indeed have had an initial higher risk of death prior taking these drugs, due to pre-existing physical or mental illnesses. This study examined non-fatal IDO episodes that resulted in hospital presentation, thereby excluding those that entailed general practice presentation only or those that go untreated by any healthcare professional. The NSHRI collects only information pertaining to treatment allocated in the emergency department, and it is therefore possible that persons who presented following non-fatal IDO may have subsequently died post-discharge or following recommended next care and potentially featured in our fatal IDO sample. Information collected on drugs used and quantity of tablets consumed in IDO was self-reported by the presenting individual, which may be subject to inaccuracy; however, these data are supplemented by ambulance service records, hospital medical records and toxicology reports where present. Finally, the certification of a drug as causal to death is established by the Coroner, using information obtained from the State Pathologist and State Laboratory for Human Toxicology, whereby the decision is based on the interoperation of the Coroner and thus may be subjective and not uniform across coronial districts.

### *Conclusion*

Male gender, increasing age and multiple drug use were associated with fatal IDO. Tricyclic antidepressants and opioids were associated with significant elevations in risk of a fatal outcome following IDO. These findings add to the current evidence regarding the risk and potential adverse outcomes associated with these drugs, which informs safe and appropriate prescribing, where clinicians

consider the fatality risk of drugs when determining treatment for patients at risk of self-harm or who have previously harmed themselves.

DRAFT

## References

- Alonso, J., Angermeyer, M. C., Bernert, S., Bruffaerts, R., Brugha, T. S., Bryson, H., de Girolamo, G., Graaf, R., Demyttenaere, K., Gasquet, I., Haro, J. M., Katz, S. J., Kessler, R. C., Kovess, V., Lepine, J. P., Ormel, J., Polidori, G., Russo, L. J., Vilagut, G., Almansa, J., Arbabzadeh-Bouchez, S., Autonell, J., Bernal, M., Buist-Bouwman, M. A., Codony, M., Domingo-Salvany, A., Ferrer, M., Joo, S. S., Martinez-Alonso, M., Matschinger, H., Mazzi, F., Morgan, Z., Morosini, P., Palacin, C., Romera, B., Taub, N., Vollebergh, W. A., & ESEMeD/Mhedea Investigators, E. S. o. t. E. o. M. D. P. (2004). Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. *Acta Psychiatr Scand Suppl*(420), 21-27.
- Austin, A. E., Proescholdbell, S. K., Creppage, K. E., & Asbun, A. (2017). Characteristics of self-inflicted drug overdose deaths in North Carolina. *Drug Alcohol Depend*, 181, 44-49.
- Bedson, J., Chen, Y., Ashworth, J., Hayward, R. A., Dunn, K. M., & Jordan, K. P. (2019). Risk of adverse events in patients prescribed long-term opioids: A cohort study in the UK Clinical Practice Research Datalink. *Eur J Pain*, 23(1), 908-922.
- Bohnert, A. S., Valenstein, M., Bair, M. J., Ganoczy, D., McCarthy, J. F., Ilgen, M. A., & Blow, F. C. (2011). Association between opioid prescribing patterns and opioid overdose-related deaths. *JAMA*, 305(13), 1315-1321.
- Brett, J., Wylie, C. E., Raubenheimer, J., Isbister, G. K., & Buckley, N. A. (2019). The relative lethal toxicity of pharmaceutical and illicit substances: A 16-year study of the Greater Newcastle Hunter Area, Australia. *Br J Clin Pharmacol*, 85(9), 2098-2107.
- Canadian Agency for Drugs and Technologies in Health (2015). Discontinuation Strategies for Patients with Long-term Benzodiazepine Use: A Review of Clinical Evidence and Guidelines. Retrieved 24th October 2019 from: [https://www.cadth.ca/sites/default/files/rc0682-bzd\\_discontinuation\\_strategies\\_final\\_0.pdf](https://www.cadth.ca/sites/default/files/rc0682-bzd_discontinuation_strategies_final_0.pdf).
- Carr, M. J., Ashcroft, D. M., Kontopantelis, E., While, D., Awenat, Y., Cooper, J., Chew-Graham, C., Kapur, N., & Webb, R. T. (2016). Clinical management following self-harm in a UK-wide primary care cohort. *J Affect Disord*, 197, 182-188.

- Chen, V. C., Cheng, A. T., Tan, H. K., Chen, C. Y., Chen, T. H., Stewart, R., & Prince, M. (2009). A community-based study of case fatality proportion among those who carry out suicide acts. *Soc Psychiatry Psychiatr Epidemiol*, 44(12), 1005-1011.
- Cibis, A., Mergl, R., Bramesfeld, A., Althaus, D., Niklewski, G., Schmidtke, A., & Hegerl, U. (2012). Preference of lethal methods is not the only cause for higher suicide rates in males. *J Affect Disord*, 136(1-2), 9-16.
- Central Statistics Office (CSO) (2014). Suicide Statistics 2011. Retrieved 24th October 2019 from: <https://www.cso.ie/en/releasesandpublications/er/ss/suicidestatistics2011/>.
- Daly, C., Griffin, E., Ashcroft, D. M., Webb, R. T., Perry, I. J., & Arensman, E. (2018). Frequently used drug types and alcohol involvement in intentional drug overdoses in Ireland: a national registry study. *Eur J Public Health*, 28(4), 681-686.
- Dodds, T. J. (2017). Prescribed Benzodiazepines and Suicide Risk: A Review of the Literature. *Prim Care Companion CNS Disord*, 19(2).
- Finkelstein, Y., Macdonald, E. M., Hollands, S., Hutson, J. R., Sivilotti, M. L., Mamdani, M. M., Koren, G., Juurlink, D. N., Canadian Drug, S., & Effectiveness Research, N. (2015a). Long-term outcomes following self-poisoning in adolescents: a population-based cohort study. *Lancet Psychiatry*, 2(6), 532-539.
- Finkelstein, Y., Macdonald, E. M., Hollands, S., Sivilotti, M. L., Hutson, J. R., Mamdani, M. M., Koren, G., Juurlink, D. N., Canadian Drug, S., & Effectiveness Research, N. (2015b). Risk of Suicide Following Deliberate Self-poisoning. *JAMA Psychiatry*, 72(6), 570-575.
- Finkelstein, Y., Macdonald, E. M., Hollands, S., Sivilotti, M. L., Hutson, J. R., Mamdani, M. M., Koren, G., Juurlink, D. N., Canadian Drug, S., & Effectiveness Research, N. (2016). Repetition of intentional drug overdose: a population-based study. *Clin Toxicol (Phila)*, 54(7), 585-589.
- Frank, J. W., Lovejoy, T. I., Becker, W. C., Morasco, B. J., Koenig, C. J., Hoeffcker, L., Dischinger, H. R., Dobscha, S. K., & Krebs, E. E. (2017). Patient Outcomes in Dose Reduction or Discontinuation of Long-Term Opioid Therapy: A Systematic Review. *Ann Intern Med*, 167(3), 181-191.
- Freeman, A., Mergl, R., Kohls, E., Szekely, A., Gusmao, R., Arensman, E., Koburger, N., Hegerl, U., & Rummel-Kluge, C. (2017). A cross-national study on gender differences in suicide intent. *BMC Psychiatry*, 17(1), 234.

- Geulayov, G., Ferrey, A., Casey, D., Wells, C., Fuller, A., Bankhead, C., Gunnell, D., Clements, C., Kapur, N., Ness, J., Waters, K., & Hawton, K. (2018). Relative toxicity of benzodiazepines and hypnotics commonly used for self-poisoning: An epidemiological study of fatal toxicity and case fatality. *J Psychopharmacol*, 32(6), 654-662.
- Griffin, E., Mc Ternan, N., Wrigley, C., Nicholson, S., Arensman, E., Williamson, E., & Corcoran, P. (2019). National Self-Harm Registry Ireland Annual Report, 2018. Retrieved 24th October 2019 from: <https://www.nsrif.ie/wp-content/uploads/2019/10/NSRF-National-Self-Harm-Registry-Ireland-Annual-Report-2018-for-website.pdf>.
- Hawton, K., Bergen, H., Simkin, S., Cooper, J., Waters, K., Gunnell, D., & Kapur, N. (2010). Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. *Br J Psychiatry*, 196(5), 354-358.
- Health Research Board (HRB) (2015). National Drug-Related Deaths Index 2004 to 2015 data. In *Health Research Bulletin*. Retrieved 24th October 2019 from: [www.drugsandalcohol.ie/28086/1/Drug-Related%20Deaths%20in%20Ireland%202004%20to%202015.pdf](http://www.drugsandalcohol.ie/28086/1/Drug-Related%20Deaths%20in%20Ireland%202004%20to%202015.pdf).
- Ilgen, M. A., Bohnert, A. S., Ganoczy, D., Bair, M. J., McCarthy, J. F., & Blow, F. C. (2016). Opioid dose and risk of suicide. *Pain*, 157(5), 1079-1084.
- Jansen, E., Buster, M. C., Zuur, A. L., & Das, C. (2009). Fatality of suicide attempts in Amsterdam 1996-2005. *Crisis*, 30(4), 180-185.
- Kelty, E., & Hulse, G. (2017). Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone. *Int J Drug Policy*, 46, 54-60.
- Kwok, C. L., Yip, P. S., Gunnell, D., Kuo, C. J., & Chen, Y. Y. (2014). Non-fatal repetition of self-harm in Taipei City, Taiwan: cohort study. *Br J Psychiatry*, 204, 376-382.
- Linsley, K. R., Schapira, K., & Kelly, T. P. (2001). Open verdict v. suicide - importance to research. *Br J Psychiatry*, 178, 465-468.
- McDonald, R., & Strang, J. (2016). Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. *Addiction*, 111(7), 1177-1187.
- Misuse of Drugs Act (1977). Irish Statute Book. Retrieved 24<sup>th</sup> October 2019 from: <http://www.irishstatutebook.ie/eli/1977/act/12/enacted/en/html>.

Misuse of Drugs Act (1984). Irish Statute Book. Retrieved 24th October 2019 from:

<http://www.irishstatutebook.ie/eli/1984/act/18/enacted/en/html>.

National Institute for Health and Care Excellence (NICE) (2018). Antidepressant treatment in adults.

Retrieved 24th October 2019 from:

<https://pathways.nice.org.uk/pathways/depression/antidepressant-treatment-in-adults>.

National Institute for Health and Care Excellence (NICE) (2011). Self-harm: longer-term management.

Retrieved 24th October 2019 from: <https://www.nice.org.uk/guidance/cg133>.

Organisation for Economic Co-operation and Development (OECD) (2019). Addressing problematic

opioid use in OECD countries. Retrieved 24th October 2019 from: [https://www.oecd-](https://www.oecd-ilibrary.org/sites/a18286f0-en/1/2/3/index.html?itemId=/content/publication/a18286f0-en&mimeType=text/html&_csp_=34900059404c1442c82fdcd9ded59a08&itemIGO=oecd&itemContentType=book)

[ilibrary.org/sites/a18286f0-en/1/2/3/index.html?itemId=/content/publication/a18286f0-](https://www.oecd-ilibrary.org/sites/a18286f0-en/1/2/3/index.html?itemId=/content/publication/a18286f0-en&mimeType=text/html&_csp_=34900059404c1442c82fdcd9ded59a08&itemIGO=oecd&itemContentType=book)

[en&mimeType=text/html&\\_csp\\_=34900059404c1442c82fdcd9ded59a08&itemIGO=oecd&ite](https://www.oecd-ilibrary.org/sites/a18286f0-en/1/2/3/index.html?itemId=/content/publication/a18286f0-en&mimeType=text/html&_csp_=34900059404c1442c82fdcd9ded59a08&itemIGO=oecd&itemContentType=book)

[mContentType=book](https://www.oecd-ilibrary.org/sites/a18286f0-en/1/2/3/index.html?itemId=/content/publication/a18286f0-en&mimeType=text/html&_csp_=34900059404c1442c82fdcd9ded59a08&itemIGO=oecd&itemContentType=book)

Okumura, Y., & Nishi, D. (2017). Risk of recurrent overdose associated with prescribing patterns of psychotropic medications after nonfatal overdose. *Neuropsychiatr Dis Treat*, 13, 653-665.

Office for National Statistics (ONS) (2019). Deaths related to drug poisoning in England and Wales:

2018 registrations. Retrieved 24th October 2019 from:

[https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bul](https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2018registrations)

[letins/deathsrelatedtodrugpoisoninginenglandandwales/2018registrations](https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2018registrations).

Perry, I. J., Corcoran, P., Fitzgerald, A. P., Keeley, H. S., Reulbach, U., & Arensman, E. (2012). The incidence and repetition of hospital-treated deliberate self harm: findings from the world's first national registry. *PLoS One*, 7(2), e31663.

Platt, S., Bille-Brahe, U., Kerkhof, A., Schmidtke, A., Bjerke, T., Crepet, P., De Leo, D., Haring, C., Lonnqvist, J., Michel, K., & et al. (1992). Parasuicide in Europe: the WHO/EURO multicentre study on parasuicide. I. Introduction and preliminary analysis for 1989. *Acta Psychiatr Scand*, 85(2), 97-104.

Pringle, K., Caupp, S., Shi, J., Wheeler, K. K., Spiller, H. A., Casavant, M. J., & Xiang, H. (2017).

Analysis of intentional drug poisonings using Ohio Poison Control Center Data, 2002-2014.


*Clin Toxicol (Phila)*, 55(7), 652-658.

Schmidtke, A., Bille-Brahe, U., De Leo, D., & Kerkhof, A. (2004). *Suicidal behavior in Europe. Results*


*from the WHO/EURO multicenter study on suicidal behavior*. Göttingen: Hogrefe & Huber.

- Sgarlato, A., & deRoux, S. J. (2015). Prescription opioid related deaths in New York City: a 2 year retrospective analysis prior to the introduction of the New York State I-STOP law. *Forensic Sci Med Pathol*, 11(3), 388-394.
- Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. *BMJ*, 357, j1550.
- Vancayseele, N., Portzky, G., & van Heeringen, K. (2016). Increase in Self-Injury as a Method of Self-Harm in Ghent, Belgium: 1987-2013. *PLoS One*, 11(6), e0156711.
- Vancayseele, N., Rotsaert, I., Portzky, G., & van Heeringen, K. (2019). Medication used in intentional drug overdose in Flanders 2008-2013. *PLoS One*, 14(5), e0216317.
- World Health Organization (WHO) (2019). Guidelines for ATC classification and DDD assignment. In: Oslo, Norway. Retrieved 24th October 2019 from: [https://www.whocc.no/filearchive/publications/2019\\_guidelines\\_web.pdf](https://www.whocc.no/filearchive/publications/2019_guidelines_web.pdf).
- Zalsman, G., Hawton, K., Wasserman, D., van Heeringen, K., Arensman, E., Sarchiapone, M., Carli, V., Hoschl, C., Barzilay, R., Balazs, J., Purebl, G., Kahn, J. P., Saiz, P. A., Lipsicas, C. B., Bobes, J., Cozman, D., Hegerl, U., & Zohar, J. (2016). Suicide prevention strategies revisited: 10-year systematic review. *Lancet Psychiatry*, 3(7), 646-659.

**Figure 1a:** Incidence rates of non-fatal intentional drug overdose, per 100,000 persons with 95% confidence intervals, by gender and age group, 2007-2014



**Figure 1b:** Incidence rates of fatal intentional drug overdose, per 100,000 persons with 95% confidence intervals, by gender and age group, 2007-2014



**Table 1:** Case fatality risks and case fatality risk ratios by demographic and intentional drug overdose characteristics, 2007-2014

Characteristics		All IDOs <sup>2</sup>	Fatal IDOs <sup>1</sup>	Case fatality risk %	Case fatality risk ratio (95% CI)
Gender	Female	37202	163	0.4 ***	Reference
	Male	26993	201	0.7	1.70 (1.38-2.09) ***
Age group	15-24 years	18820	35	0.2 ***	Reference
	25-44 years	29795	166	0.6	3.00 (2.08-4.31) ***
	≥45 years	15580	163	1.0	5.63 (3.91-8.11) ***
IDO type	Single drug IDO	32931	79	0.2 ***	Reference
	Multiple drug IDO	31260	285	0.9	3.80 (2.96-4.88) ***
Number of drugs	1	32931	79	0.2 ***	Reference
	2-5	30895	232	0.8	3.13 (2.43-4.04) ***
	≥6	365	53	14.5	60.5 (42.7-85.7) ***
Alcohol involvement	Yes	27656	151	0.5	Reference
	No	36539	213	0.6	1.07 (0.87-1.32)

<sup>1</sup> Fatal IDOs include all IDOs which resulted in death within the study.

<sup>2</sup> All IDOs include all fatal and non-fatal IDOs within the study.

Statistical significance =p≤0.05, \*\*=p≤0.01, \*\*\* = p≤0.001.

**Table 2:** The number and rates of non-fatal and fatal intentional drug overdose where the drug caused death, and the associated case fatality risk and case fatality risk ratios, by gender, 2007-2014

Drug	All IDOs <sup>1</sup>		Fatal IDOs <sup>2</sup>		Case fatality	
	Number	Rate per 100,000 (95% CI)	Number	Rate per 100,000 (95% CI)	Case fatality risk %	Case fatality risk ratio (95% CI)
<b>Both genders</b>						
<b>Psycholeptics<sup>3</sup></b>	27970	77.6 (76.7-78.5)	166	0.46 (0.39-0.53)	0.69 (0.56-0.84) ***	2.41 (1.65-3.52) ***
<b>Antipsychotics</b>	6589	18.3 (17.8-18.7)	55	0.15 (0.11-0.19)	0.64 (0.46-0.90) **	3.28 (2.14-5.02) ***
<b>Anxiolytics</b>	14778	41.0 (40.3-41.7)	78	0.22 (0.17-0.27)	0.57 (0.44-0.76) ***	2.08 (1.39-3.10) ***
<b>Hypnotics and sedatives</b>	13130	36.4 (35.8-37.1)	96	0.27 (0.21-0.32)	0.64 (0.49-0.82) ***	2.89 (1.94-4.31) ***
<b>Benzodiazepines</b>	24626	68.3 (67.5-69.2)	136	0.38 (0.31-0.44)	0.64 (0.51-0.79) ***	2.16 (1.48-3.16) ***
<b>Psychoanaleptics<sup>4</sup></b>	13797	38.3 (37.6-38.9)	141	0.39 (0.32-0.45)	0.75 (0.61-0.94) **	4.41 (3.03-6.42) ***
<b>Antidepressants</b>	13600	37.7 (37.1-38.4)	141	0.39 (0.33-0.46)	0.75 (0.61-0.94) **	4.46 (3.06-6.49) ***
<b>Tricyclics</b>	1307	3.63 (3.43-3.83)	52	0.14 (0.10-0.18)	0.89 (0.62-1.29)	15.1 (9.90-23.2) ***
<b>SSRIs</b>	7669	21.3 (20.8-21.8)	56	0.16 (0.11-0.20)	0.69 (0.49-0.97) *	3.15 (2.09-4.75) ***
<b>Opioids</b>	2830	7.85 (7.56-8.15)	79	0.22 (0.17-0.27)	0.84 (0.62-1.12)	12.9 (8.60-19.3) ***
<b>Non-opioid analgesic</b>	18031	50.0 (49.3-50.8)	40	0.11 (0.08-0.15)	0.35 (0.24-0.50)	Reference
<b>Antiepileptics</b>	4634	12.9 (12.5-13.2)	25	0.07 (0.04-0.10)	0.63 (0.38-1.04)	1.96 (1.17-3.29) **
<b>Illicit drugs</b>	3944	10.94 (11.3-10.9)	34	0.09 (0.06-0.13)	0.72 (0.46-1.11)	4.02 (2.36-6.86) ***
<b>Males</b>						
<b>Psycholeptics</b>	12205	68 (66.8-69.2)	87	0.48 (0.39-0.59)	0.66 (0.50-0.87)	1.98 (1.20-3.26) **
<b>Antipsychotics</b>	2763	15.4 (14.8-16)	20	0.11 (0.06-0.16)	0.51 (0.30-0.87) **	1.89 (1.01-3.52) *
<b>Anxiolytics</b>	6744	37.6 (36.7-38.5)	39	0.22 (0.15-0.29)	0.56 (0.38-0.82) **	1.58 (0.93-2.69)
<b>Hypnotics and sedatives</b>	5336	29.7 (28.9-30.5)	49	0.27 (0.19-0.35)	0.67 (0.47-0.96) *	2.49 (1.47-4.21) ***
<b>Benzodiazepines</b>	10797	60.1 (59.0-61.3)	70	0.39 (0.30-0.48)	0.63 (0.47-0.85) **	1.76 (1.06-2.91) *
<b>Psychoanaleptics</b>	4967	27.7 (26.9-28.5)	57	0.32 (0.23-0.40)	0.70 (0.50-0.98) *	3.10 (1.87-5.15) ***
<b>Antidepressants</b>	4868	27.1 (26.3-27.9)	57	0.32 (0.23-0.40)	0.70 (0.50-0.98) *	3.14 (1.89-5.22) ***
<b>Tricyclics</b>	472	2.63 (2.39-2.87)	17	0.09 (0.05-0.14)	0.89 (0.46-1.69)	9.02 (4.74-17.19) ***
<b>SSRIs</b>	2655	14.8 (14.2-15.4)	29	0.16 (0.10-0.22)	0.69 (0.43-1.10)	3.01 (1.73-5.24) ***

<b>Opioids</b>	1175	6.55 (6.16-6.93)	43	0.24 (0.17-0.31)	0.81 (0.54-1.20)	11.1 (6.47-19.1) ***
<b>Non-opioid analgesic</b>	6213	34.6 (33.7-35.5)	22	0.12 (0.07-0.17)	0.33 (0.21-0.54) ***	Reference
<b>Antiepileptics</b>	1805	10.1 (9.6-10.5)	12	0.07 (0.03-0.11)	0.76 (0.36-1.60)	1.69 (0.83-3.41)
<b>Illicit drugs</b>	2897	16.1 (15.5-16.7)	30	0.17 (0.11-0.23)	0.72 (0.45-1.16)	4.20 (2.27-7.76) ***
<b>Females</b>						
<b>Psycholeptics</b>	15615	85.9 (84.5-87.2)	79	0.43 (0.34-0.53)	0.72 (0.54-0.96) *	2.91 (1.63-5.19) ***
<b>Antipsychotics</b>	3826	21 (20.4-21.7)	35	0.19 (0.13-0.26)	0.75 (0.49-1.17)	5.34 (2.89-9.85) ***
<b>Anxiolytics</b>	8034	44.2 (43.2-45.2)	39	0.21 (0.15-0.28)	0.60 (0.40-0.89) **	2.77 (1.51-5.08) ***
<b>Hypnotics and sedatives</b>	7794	42.9 (41.9-43.8)	47	0.26 (0.18-0.33)	0.61 (0.42-0.87) **	3.44 (1.87-6.35) ***
<b>Benzodiazepines</b>	13829	76 (74.7-77.3)	66	0.36 (0.27-0.45)	0.64 (0.47-0.87) **	2.69 (1.50-4.83) ***
<b>Psychoanaleptics</b>	8830	48.6 (47.5-49.6)	84	0.46 (0.36-0.56)	0.79 (0.60-1.06)	6.32 (3.57-11.2) ***
<b>Antidepressants</b>	8732	48 (47.0-49.0)	84	0.46 (0.36-0.56)	0.79 (0.60-1.06)	6.37 (3.60-11.3) ***
<b>Tricyclics</b>	835	4.59 (4.27-4.91)	35	0.19 (0.13-0.26)	0.90 (0.57-1.41)	23.6 (13.0-43.0) ***
<b>SSRIs</b>	5014	27.6 (26.8-28.3)	27	0.15 (0.09-0.21)	0.72 (0.45-1.16)	3.32 (1.80-6.13) ***
<b>Opioids</b>	1655	9.10 (8.65-9.55)	36	0.20 (0.13-0.26)	0.88 (0.56-1.37)	15.4 (8.38-28.2) ***
<b>Non-opioid analgesic</b>	11758	64.6 (63.5-65.8)	18	0.10 (0.05-0.15)	0.37 (0.21-0.63) ***	Reference
<b>Antiepileptics</b>	2829	15.6 (15.0-16.1)	13	0.07 (0.03-0.11)	0.55 (0.28-1.07)	2.40 (1.19-5.15) *
<b>Illicit drugs</b>	1047	5.76 (5.40-6.11)	<5	-	0.67 (0.19-2.38)	3.29 (1.00-10.8) *

<sup>1</sup> All IDOs include fatal and non-fatal IDOs where the drug did not cause death.

<sup>2</sup> Fatal IDOs include fatal IDOs where the drug caused death.

<sup>3</sup> Psycholeptics are psychoactive drugs used to depress mental activity and include antipsychotics, anxiolytics, and hypnotics and sedatives.

<sup>4</sup> Psychoanaleptics are stimulant drugs including antidepressants, psychostimulants, nootropics anti-dementia drugs and combinations with psycholeptics.

The case fatality risk ratio presented here is weighted and thus involves analyses whereby the drug of interest is counted as half within the reference drug group (e.g. non-opioid analgesics) and half within the drug group of interest. The process of weighting was performed to address the challenge of calculating case fatality risk ratios when multiple drugs caused death.

The case fatality risk ratios presented for both genders are adjusted for age.

Statistical significance =p≤0.05, \*\*=p≤0.01, \*\*\* = p≤0.001.

**Table 3:** The numbers and rates of non-fatal and fatal intentional drug overdose where individual drug caused death, and the associated case fatality risk and case fatality risk ratios (95% confidence intervals), by gender, 2007-2014

Drug	All IDOs <sup>1</sup>		Fatal IDOs <sup>2</sup>		Case fatality	
	Number	Rate per 100,000 (95% CI)	Number	Rate per 100,000 (95% CI)	Case fatality risk %	Case fatality risk ratio (95% CI)
<b>Both genders</b>						
<b>Tricyclics</b>						
Amitriptyline	784	2.18 (2.02-2.33)	37	0.10 (0.07-0.14)	0.89 (0.58-1.38)	Reference
Dosulepin	288	0.80 (0.70-0.89)	13	0.04 (0.02-0.06)	0.91 (0.44-1.92)	0.93 (0.49-1.76)
Trimipramine	58	0.16 (0.12-0.20)	<5	-	1.04 (0.15-7.35)	0.71 (0.18-3.02)
<b>SSRIs</b>						
Fluoxetine	1640	4.55 (4.33-4.78)	9	0.02 (0.01-0.04)	0.91 (0.37-2.23)	Reference
Citalopram	1279	3.55 (3.35-3.75)	41	0.11 (0.08-0.15)	0.73 (0.49-1.09)	5.26 (2.55-10.85) ***
Sertraline	1014	2.81 (2.64-2.99)	<5	-	0.45 (0.14-1.46)	0.74 (0.23-2.39)
<b>Opioids</b>						
Tramadol	1778	4.93 (4.70-5.17)	32	0.09 (0.06-0.12)	0.89 (0.53-1.34)	Reference
Oxycodone	287	0.80 (0.70-0.89)	24	0.07 (0.04-0.09)	0.98 (0.57-1.70)	3.94 (2.30-6.77) ***
Morphine	133	0.37 (0.31-0.43)	12	0.03 (0.01-0.05)	0.81 (0.39-1.69)	4.16 (2.11-8.19) ***
<b>Males</b>						
<b>Tricyclics</b>						
Amitriptyline	274	1.53 (1.34-1.71)	10	0.06 (0.02-0.09)	0.81 (0.35-1.84)	Reference
Dosulepin	106	0.59 (0.48-0.71)	6	0.03 (0.01-0.06)	1.06 (0.34-3.29)	1.41 (0.51-3.89)
Trimipramine	21	0.12 (0.07-0.17)	<5	-	10.5 (0.66-16.8)	1.26 (0.16-9.86)
<b>SSRIs</b>						
Fluoxetine	550	3.06 (2.80-3.33)	<5	-	1.01 (0.25-4.03)	Reference
Citalopram	449	2.50 (2.27-2.74)	20	0.11 (0.06-0.16)	0.76 (0.43-1.35)	5.90 (2.01-17.28) ***
Sertraline	323	1.80 (1.60-2.00)	<5	-	0.38 (0.10-1.45)	1.28 (0.29-5.28)
<b>Opioids</b>						
Tramadol	714	3.98 (3.68-4.28)	17	0.09 (0.05-0.14)	0.83 (0.44-1.58)	Reference

<b>Oxycodone</b>	137	0.76 (0.63-0.89)	11	0.06 (0.02-0.10)	1.00 (0.44-2.28)	3.11 (1.45-6.66) **
<b>Morphine</b>	80	0.45 (0.35-0.55)	6	0.03 (0.01-0.06)	0.63 (0.23-1.71)	2.85 (1.12-7.28) *
<b>Females</b>						
<b>Tricyclics</b>						
<b>Amitriptyline</b>	510	2.80 (2.56-3.05)	27	0.15 (0.09-0.21)	0.93 (0.55-1.55)	<i>Reference</i>
<b>Dosulepin</b>	182	1.00 (0.85-1.15)	7	0.04 (0.01-0.07)	0.82 (0.30-2.20)	0.73 (0.32-1.68)
<b>Trimipramine</b>	37	0.20 (0.14-0.27)	<5	-	1.03 (0.64-16.43)	0.51 (0.69-3.76)
<b>SSRIs</b>						
<b>Fluoxetine</b>	1090	6.0 (5.63-6.36)	5	0.03 (0.00-0.05)	0.84 (0.26-2.75)	<i>Reference</i>
<b>Citalopram</b>	830	4.56 (4.25-4.88)	21	0.12 (0.07-0.17)	0.70 (0.40-1.22)	4.69 (1.76-12.49) **
<b>Sertraline</b>	691	3.80 (3.51-4.09)	<5	-	1.00 (0.06-16.01)	0.32 (0.04-2.70)
<b>Opioids</b>						
<b>Tramadol</b>	1064	5.85 (5.49-6.21)	15	0.08 (0.04-0.13)	0.85 (0.43-1.68)	<i>Reference</i>
<b>Oxycodone</b>	150	0.82 (0.69-0.96)	13	0.07 (0.03-0.11)	0.96 (0.46-2.02)	5.06 (2.33-11.0) ***
<b>Morphine</b>	53	0.29 (0.21-0.37)	6	0.03 (0.01-0.06)	1.13 (0.36-3.50)	6.67 (2.54-17.5) ***

<sup>1</sup> All IDOs include fatal and non-fatal IDOs where the drug did not cause death.

<sup>2</sup> Fatal IDOs include fatal IDOs where the drug caused death.

The case fatality risk ratio presented here is weighted and thus involves analyses whereby the drug of interest is counted as half within the reference drug group (non-opioid analgesics) and half within the drug group of interest. The process of weighting was performed to address the challenge of calculating case fatality risk ratios when multiple drugs caused death.

The case fatality risk ratios presented for both genders are adjusted for age.

Statistical significance =p≤0.05, \*\*=p≤0.01, \*\*\* = p≤0.001.

## **Acknowledgements**

This research was supported by funding from the University of Manchester and the National Suicide Research Foundation, which is in receipt of funding from the National Office for Suicide Prevention, Ireland. The authors would like to acknowledge colleagues at the National Drug-Related Deaths Index for providing us with the fatal IDO and subsequent guidance on its use and interpretation. Furthermore, the authors would like to thank the Data Registration Officers for their important contribution in collecting information on self-harm presentations to hospitals across the Republic of Ireland.

DRAFT

### **Disclosure of interest**

Caroline Daly, Eve Griffin, Roger T. Webb, Paul Corcoran, Ivan J. Perry and Ella Arensman have no conflicts of interest to disclose. Darren M. Ashcroft has, outside of the submitted work, received grants from Abbvie, Almirall, Celgene, Eli Lilly, Novartis, UCB and the Leo Foundation.

DRAFT